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Abstract 
Background 
Human rhinoviruses (HRV) commonly precipitate asthma exacerbations. TLR3, an innate 
pattern-recognition receptor, is triggered by HRV driving inflammation that may worsen 
asthma.  
Objective  
To evaluate an inhibitory monoclonal antibody to TLR3, CNTO3157, on experimental HRV-16 
inoculation in healthy and asthmatic subjects. 
Methods 
In this double-blind multicenter randomized parallel-group study in North America and Europe, 
healthy and mild-moderate stable asthmatic subjects received single or multiple doses of CNTO 
3157 or placebo, respectively, and were then inoculated with HRV-16 within 72 hours. All 
subjects were monitored for respiratory symptoms, lung function, and nasal viral load. The 
primary endpoint was maximal decline in forced expired volume in 1 second (FEV1) during 10-
days post-inoculation.  
Results 
In asthmatic subjects (N=63), CNTO3157 provided no protection against FEV1 decline (LS mean 
[SE]: CNTO3157 (n=30) = -7.08 [8.15] % and placebo (n=25) = -5.98 [8.56] %), or symptoms post- 
inoculation. In healthy subjects (N=12), CNTO3157 versus placebo significantly attenuated 
upper (p=0.03) and lower (p=0.02) airway symptom scores, with area-under-the-curve 
increases of 9.1(15.1) vs 34.9 (17.6) and 13.0 (18.4) vs 50.4 (25.9) for the CNTO3157 group (n=8) 
and placebo group (n=4), respectively, after inoculation. All of the severe and three of the four 
non-serious asthma exacerbations occurred on CNTO3157.  
Conclusion 
In summary, CNTO3157 was ineffective in attenuating the impact of HRV-16 challenge on lung 
function, asthma control, and symptoms in asthma, but suppressed cold symptoms in healthy 
subjects. Other approaches, including blockade of multiple pathways, or antiviral agents, need 
to be sought for this high unmet medical need. 
Key Messages 
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• TR3 signaling is triggered by common respiratory viruses and could play a role in the 
worsening airway inflammation in asthma exacerbations of viral origin.  
• Blockade of TLR3 was ineffective in attenuating the respiratory manifestations of 
experimental rhinovirus challenge in mild-moderate persistent asthmatic subjects but 
did suppress cold symptoms in healthy volunteers. 
Capsule summary 
Blockade of TLR3, a major viral-sensing receptor, was ineffective in reducing the impact of 
rhinovirus infection, a common precipitant of asthma exacerbations, on asthma symptoms and 
lung function.  
Key words: asthma, viral infection, inflammation, TLR3 
Public registry numbers: The study was registered on the clinicaltrials.gov website (US 
registration number= NCT01704040) and the EU registration site (EudraCT), (registration 
number= 2011-005369-19). 
The study was sponsored by Janssen R&D, Spring House, PA, USA 
Abbreviations  
ACQ7 Asthma Control Questionnaire 7 
ADA antidrug antibodies  
AE adverse event 
AM morning 
AUC area under the curve 
BD bronchodilator 
CCSS Cold and Chest Symptom Scale 
CCL C-C motif chemokine ligand 
CSAS Cold Symptom Assessment Score 
CPE Cytopathic effect 
CRP C-reactive protein 
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CST cystatin  
CXCL C-X-C motif ligand 
dsRNA Double stranded ribonucleic acid 
ECG elecrocardiogram 
FENO fractional concentration of exhaled nitric oxide 
FEV1 forced expired volume in 1 second 
HC Healthy controls 
HRV human rhinovirus  
HSV-1 herpes simplex virus 1 
ICS inhaled corticosteroid 
IFN interferon 
IL interleukin 
IP10 interferon gamma-induced protein 10 
LS  least squares 
MCP macrophage chemoattractant protein 
MDA-5 melanoma differentiation associated gene-5 
mITT modified intention to treat  
MRC Medical Research Council 
PD pharmacodynamics  
PEFR peak expiratory flow rate 
PI post-inoculation 
PK pharmacokinetics 
poly-I:C polyinosinic:polycytidylic acid 
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PRR pattern recognition receptors 
RANTES Regulated on Activation, Normal T Cell Expressed and Secreted 
RIG-I retinoic acid inducible gene- I  
Pre-BD pre-bronchodilator 
RNA ribonucleic acid 
sIL-33R Soluble IL-33 receptor 
TCID tissue culture infective dose 
TEAE treatment-emergent adverse event  
TLR3 Toll like receptor 3 
TNOSS Total Nasal and Ocular Symptom Score  
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Introduction 
Acute asthma exacerbations are episodes of worsening symptoms that may lead to 
augmentation of asthma therapy, hospitalization, and on occasions death. Asthma 
exacerbations are most often associated with respiratory viruses, with an estimated 65-85% of 
all viral exacerbations in children and 50% in adults being caused by human rhinovirus (HRV).  
While symptoms due to HRV are usually restricted to the upper airway in non-asthmatic 
subjects, in asthma, lower respiratory symptoms including cough, dyspnea, and wheezing are 
common. The mechanisms may include direct infection of the lower airway 
1, 2
, with worsening 
of inflammation due to host defense mechanisms. The pathogenesis of HRV in the upper and 
lower airway  has been extensively reviewed 
3
. HRV infects a subset of cells in the respiratory 
epithelium, and viral replication initiates antiviral and pro-inflammatory responses through 
several molecular pathways.   
Pattern recognition receptors (PRR) that respond to HRV include several toll like receptors 
(TLR)s including TLR3, as well as the ribonucleic acid (RNA) helicases, melanoma differentiation 
associated gene-5 (MDA-5) and retinoic acid inducible gene- I (RIG-I)
4
.  Inflammatory mediators 
released due to PRR signaling pathways include Type I interferons (IFN-α/-ß), and Type III 
interferons (IFN-λ1-4), interleukin (IL)-6, IL-12, and IL-15 
4, 5
. Additionally, chemokines including 
C-X-C motif ligand (CXCL)10/IFN gamma-induced protein (IP-10) 
6
 drive the recruitment of 
inflammatory cells, e.g. natural killer cells and Type 1 lymphocytes.  
Preclinical studies demonstrated that an anti-TLR3 monoclonal antibody (mAb) can block 
polyinosinic:polycytidylic acid (poly(I:C))-induced inflammation in-vivo and in vitro 
7
, and can 
down-regulate poly(I:C)-induced production of inflammatory cytokines/chemokines (IL-6, IL-
8/CXCL8, CCL2/MCP-1, CCL5/ Regulated on Activation, Normal T Cell Expressed and Secreted 
(RANTES), and CXCL10 /IP-10 in human lung epithelial cells) 
8
. Antagonism of TLR3 also reduced 
mortality in an in-house mouse influenza model (unpublished data), consistent with published 
studies using TLR3-deficient mice 
9-11
. We hypothesized that blockade of TLR3 signaling would 
attenuate the impact of HRV infection in asthma. 
CNTO3157 is a fully human IgG4 kappa mAb that binds cell-surface TLR3, prevents association 
of dsRNA with TLR3, and thereby inhibits TLR3 signaling-dependent generation of cytokines and 
other inflammatory mediators. Extensive published human in vitro and murine in vivo 
experiments supported the hypothesis that CNTO 3157 would be an effective agent to suppress 
the inflammatory effects induced by rhinovirus infection (see online repository Section E1) 
Herein, we present the impact of CNTO3157 compared to placebo on the respiratory 
manifestations of inoculation with HRV-16 in healthy subjects and in subjects with mild-
moderate persistent asthma.   
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Methods 
Study Design 
This was a 2-part, randomized, multicenter, double-blind, parallel-design, placebo-controlled 
study to evaluate the efficacy and safety of CNTO3157 preceding inoculation with HRV-16. The 
study was approved by regional health authorities and ethics committees relevant for each 
investigational site. All participants demonstrated understanding of the study procedures and 
provided written consent before any study procedures.   The full study protocol can be found at 
the following link (TBD).  
Subjects 
Healthy non-smoking control subjects (HC) and subjects with mild to moderate persistent 
asthma aged 18-65 years were recruited. HC were required to have no clinically significant 
abnormalities as determined by medical history, physical examination, blood laboratory 
parameters, and electrocardiography.  
Asthma subjects had a physician diagnosis of mild to moderate asthma for at least 6 months 
prior to screening, recently stable asthma based on physician assessment, an Asthma Control 
Score 7 (ACQ7) 
12
 symptom score of <1.5 (amended later in the study to <2.5) and a pre-
bronchodilator (BD) FEV1 ≥65 % predicted. Low to medium dose inhaled corticosteroids (ICS) 
(based on the National Heart, Lung, and Blood Institute Guidelines 
13
 were permitted with 
additional controllers excluding oral corticosteroids and biologic therapies.  Subjects with prior 
life-threatening asthma were excluded.  
Subjects had a titer of serum neutralizing antibodies to HRV-16 ≤2-fold dilution, and previous 
serological confirmation of prior infection with herpes simplex 1 (HSV-1) due to associations of 
null TLR3 polymorphisms and childhood HSV-1 encephalitis 
14
.  
Randomization  
Based on a computer-generated randomization schedule prepared before the study by an 
interactive voice or web response system provider, healthy subjects in Part 1 were randomly 
assigned to 1 of 2 treatment groups in a 2:1 ratio (CNTO 3157 versus placebo) and asthma 
subjects in Part 2 were randomly assigned to 1 of 2 treatment groups in a 1:1 ratio (CNTO 3157 
versus placebo). The placebo used in the study consisted of the identical diluent used for 
CNO3157 with no discernible visual differences prepared on the day of administration by an 
independent person e.g. a pharmacist, who was not part of the study team.  
Dose selection 
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The dosing regimen selected for CNTO3157 had been previously evaluated for safety, PK and 
PD effects in the first in human study in healthy volunteers, who received ascending single 
doses up to 10mg/kg, and in asthmatic subjects, who received 4 doses up to 10mg/kg of 
CNTO3157 at weekly intervals (NCT01195207). More details can be found in the online 
repository in Section E1. 
Part 1: Healthy Subjects 
The principal objective of Part 1 was to evaluate the safety of CNTO3157 followed by nasal 
inoculation of HRV-16 in approximately 12 healthy adult subjects.   
Healthy subjects attended 2 screening visits to confirm eligibility and were then randomized on 
Day 1 using a 2: 1 ratio to receive a single IV dose of CNTO3157, 10mg/kg, or matching placebo, 
followed by inoculation of HRV-16 within 24 to 72 hours. Subjects attended the study unit daily 
for 5 days, at Day 7, and at Day 10 post-inoculation for study assessments and follow-up of 
adverse events (AEs). Additional follow-up visits occurred at approximately 4 and 8 weeks post-
randomization.  Figure 1 presents a schematic of the study design for Part 1 (upper panel). 
Part 1:  Outcome Measures 
Outcome measures included safety, pharmacokinetics (PK), and immunogenicity. The severity 
of the HRV-16-induced upper respiratory tract infection was assessed once daily using a cold 
symptoms assessment scale (CSAS) based on a modified Jackson scale 
15
, and a combined cold 
and chest symptom score (CCSS) that was based on Jackson et al 
16
 (questionnaire provided by 
SLJ). Additional assessments included exhaled nitric oxide (FENO), spirometry, blood 
biomarkers, and nasal lavage for viral assessments.    
Part 2: Subjects with mild-moderate persistent asthma 
The principal objective was to evaluate the efficacy of CNTO3157 for attenuating upper and 
lower respiratory manifestations following HRV-16 inoculation.  We hypothesized that TLR3 
blockade would attenuate the respiratory manifestations of HRV-16 in asthma.  
Subjects attended up to 3 screening visits and were then randomly assigned using a 1:1 
allocation to intravenous (I/V) CNTO3157 10mg/kg or placebo on Day 1, followed by 3 
additional weekly doses of CNTO3157 3mg/kg I/V or placebo followed by inoculation of HRV-16 
within 24-72 hours of the last dose. Subjects attended the study unit daily for 5 days, and then 
at Day 7 and Day 10 post-inoculation for study assessments including spirometry. Additional 
follow-up visits occurred at approximately 7 and 11 weeks post-randomization. Figure 1 (lower 
panel) presents a schematic of the study design for Part 2 . 
Part 2 outcome measures 
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The primary endpoint was the maximum % decrease relative to pre-inoculation in all pre-BD 
FEV1 measurements assessed at each visit from Day 1 to Day 10 post-inoculation (PI).  Major 
secondary endpoints included the CCSS, the CSAS, area under the curve (AUC) AM peak flow 
rate (PEFR) and AUC pre-BD FEV1, both over the 10 days post-inoculation, and the change from 
baseline in ACQ7 at day 10 post-inoculation.  
Other endpoints include FENO, a total nasal and ocular symptom score (TNOSS), which was 
assessed during the pre-inoculation treatment phase to assess any anti-allergic benefit, 
nocturnal awakenings, and rescue medication use.   Other assessments included the incidence 
of AEs, PK, and immunogenicity.  
Biomarker assessments  
Whole blood, serum, and nasal lavage samples and nasal brushing (Part 2 only) for biomarker 
analyses were collected and analyzed for the presence/absence of HRV-16, HRV-16 titers, and 
other biomarkers. Biomarkers were assessed in nasal lavage, blood, and sputum for proteomics 
(Somalogics platform) and transcriptomics. A subset of subjects participated in sputum 
induction during screening, before, and after inoculation with HRV-16. Detailed biomarker 
analyses can be found in Section E2 of the online repository.  
HRV challenge virus 
The strain of HRV-16 used was isolated via nasal lavage from a subject in a clinical study at the 
University of Virginia. Details about the origin of the virus appear in Section E3 of the online 
repository. A confirmed infection with HRV-16 was defined as a positive culture from nasal 
lavage at any time in the 5 days post-inoculation, and/or a 4-fold serological conversion to HRV-
16 assessed at the week 8 or 11 visits.   
Safety 
Safety was evaluated by assessment of adverse events, clinical laboratory tests (hematology, 
serum chemistry, and urinalysis), vital signs, physical examinations and electrocardiograms 
(ECG). Safety data obtained during the study were unblinded and reviewed on a routine basis 
by an independent data monitoring committee.  
The safety analysis set included all subjects who received at least one dose of CNTO3157.  If an 
event was judged by the investigator to be related to study agent, investigators had the option 
of attributing AEs to active drug, placebo, or the HRV-16 inoculum.   
Asthma exacerbations were defined a priori as “severe” or “moderate”.  Severe exacerbations 
were defined as worsening of asthma requiring use of systemic corticosteroids and/or 
hospitalization. Moderate exacerbations were defined as a deterioration in lung function (≥30% 
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decrease in the mean AM PEFR from baseline) lasting for 2 days or more, and/or increased 
rescue bronchodilator use (≥3 additional puffs of rescue medication in 24 hours over the mean 
rescue medication use defined as the mean number of puffs taken during the 7 days prior to 
randomization).   
Statistical analysis 
The sample size calculation was based on the primary endpoint, the maximum percent 
decrease relative to baseline in the pre-BD FEV1 measurements assessed at each visit through 
10 days following inoculation with HRV-16. Based on Message et al 
17
, for 80% power to detect 
a relative reduction in FEV1 of 50% (from 13% decline for placebo to 6.5%) with a standard 
deviation (SD) of 10% using a 2-sided t-test at a 0.1 level of significance, 60 subjects (30/arm) 
were required. A 0.1 level of significance was selected because this was an early development 
proof of concept study.  
Demographic and baseline disease characteristic data were summarized by treatment group. 
Descriptive statistics were used to summarize continuous variables. Counts and percentages 
were used to summarize categorical variables. Categorical data were analyzed using 
appropriate tests (chi-square tests, CMH chi-square tests, or logistic regression). Continuous 
responses were analyzed using the same statistical method as in the primary efficacy analysis. 
Nonparametric methods were adopted when the normality assumption was violated. For 
efficacy analysis, data was analyzed according to the assigned treatment group. No corrections 
were made for multiple comparisons.  
Primary efficacy analyses in Part 2 was based on a modified intention to treat (mITT) HRV set 
including randomized subjects who received at least 1 (partial or complete) dose of CNTO3157 
or placebo, had at least 1 efficacy measurement prior to HRV-16 inoculation, were inoculated 
with HRV-16, and had at least 1 post-inoculation efficacy measurement during HRV-16 infection 
phase. The mITT set was defined as subjects who received at least 1 (partial or complete) dose 
of CNTO3157 or placebo, had at least 1 efficacy measurement prior to study agent infusion, and 
had at least 1 post treatment efficacy measurement during the treatment phase.  
Safety, PK, and pharmacodynamic (PD) analyses in Part 1 and Part 2 included all subjects 
treated with study agent and were summarized based on the actual treatment received. Some 
safety, PK, and PD analyses were performed on the population inoculated with HRV-16. 
The sponsor of the study, Janssen R&D Inc., wrote the protocol, and performed the analysis of 
the study. This manuscript was written by Janssen and reviewed by all authors.   
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Results 
Disposition 
 
Part 1 was conducted at a single center in Belgium, while Part 2 was conducted at multiple sites 
in Canada, Denmark, Germany, Great Britain, and the Netherlands, from Sep 24th 2012 until 
Nov 17 2014. The screen failure rate was high (~93%) (771 subjects screened to randomize 63 
subjects), driven primarily by serological entry requirements (HRV-16 negative and HSV-1 
positive).  Figure 2 displays the disposition of subjects in the study, which had a high 
completion rate.  
 
Part 1: healthy subjects 
 
Thirteen healthy subjects were randomized into Part 1. Nine subjects received CNTO3157 and 4 
placebo; 1 subject on active therapy was not inoculated due to an AE of vomiting, attributed to 
viral gastroenteritis. Baseline demographics were similar across the two treatment groups. All 
subjects were white with a mean age of 53.6 years (ranging from 34 to 65 years) and primarily 
(61.5%) male.  All inoculated subjects on CNTO3157 and placebo had confirmed infection with 
HRV-16 as defined in the methods section.  No deaths, serious AEs, or other significant AEs 
occurred. The vast majority of AEs were mild in severity and self-limiting, and none were 
reported as related to CNTO3157. Seven subjects on CNTO3157 experienced at least 1 AE 
(77.8%) compared with 4 subjects (100%) on placebo.  
 
There was significant inhibition (p=0.03) of the CSAS in subjects on CNTO3157 compared with 
placebo, with a mean (SD) AUC of the change from pre-inoculation through 10 days post-
inoculation of 9.1(15.1) for the CNTO3157 group vs 34.9 (17.6) for the placebo group. Similarly, 
there was significant inhibition (p=0.02) of the CCSS in subjects on CNTO3157 compared with 
placebo, with a mean (SD) AUC of the change from pre-inoculation through 10 days post-
inoculation of 13.0 (18.4) for the CNTO3157 group vs 50.4 (25.9) for the placebo group, as 
depicted in Figure 3.  
Part 2: asthmatic subjects 
Demographical characteristics 
The mean age of the asthmatic subjects was 38.9 years (range 18 to 65 years), and subjects 
were primarily (65.1%) male. Demographics and disease characteristics were generally similar 
between treatment groups. Sixty (95.2%) of the subjects were white. The asthma 
characteristics of randomized subjects are summarized in Table 1. Overall, disease 
characteristics were similar across treatment groups, with no significant between-group 
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differences. In general, the asthma of the subjects was mild in severity and well-controlled on 
enrolment (mean ACQ7 scores <1.0).  A higher proportion of subjects in the placebo group 
(70%) vs 58% of subjects on CNTO3157 reported ICS use at enrolment. 
Disposition 
 
Sixty-three asthmatic subjects were randomized of whom 61 subjects received at least 1 dose 
of the study medication with 53 subjects completing all 4 doses. Thirty CNTO 3157 subjects and 
25 placebo subjects were inoculated with HRV-16. All 61 randomized subjects completed all 
scheduled visits. The proportion of confirmed infected subjects in the CNTO3157 group (24/30 
80.0%) was significantly lower than the placebo group (22/25; 88.0%), p=0.031. 
 
Primary endpoint 
For the primary analysis set inoculated with HRV (modified intention to treat [mITT] HRV), no 
significant difference (p=0.60) was found between treatment groups for percentage change 
post inoculation from pre-inoculation baseline in pre-bronchodilator (pre-BD) FEV1 (LS mean 
[SE]: CNTO3157 group (n=30) = -7.08 [8.15] % and placebo group (n=25) = -5.98 [8.56] %).  
Two pre-specified sensitivity analyses were performed for the primary efficacy endpoint. 
Sensitivity analysis 1 included only those subjects who had all scheduled pre-BD FEV1 
measurements for 10 consecutive days following inoculation with HRV-16 (24/25 on placebo 
and 27/30 on CNTO3157). Sensitivity analysis 2 directly compared the treatment effect among 
those subjects in the mITT HRV analysis set (n=55) who were infected after inoculation with 
HRV-16 (22 on CNTO3157 and 24 on placebo). No significant differences were found between 
subgroups for sensitivity analyses 1 and 2 of the primary efficacy endpoint. 
The following pre-specified subgroups were analyzed using baseline disease characteristics and 
concomitant asthma therapy (use of ICS): 
• Pre-BD FEV1 (< Median, ≥ Median). 
• Exhaled nitric oxide (FENO); <Median ≥ Median) 
• Blood eosinophils (< Median, ≥ Median) 
• ACQ7 symptom score (> 1.5, ≤ 1.5) 
• ICS use (Yes, No) 
There were no significant differences observed in any of the subgroup analyses that were 
conducted in regard to the primary endpoint. 
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Figure 4 shows the percentage change in pre-BD FEV1 from pre-inoculation baseline to 21 days 
post-inoculation for the primary analysis set. The fall in FEV1 was approximately 50% of 
expected based on powering assumptions as detailed in the methods section.  
Secondary endpoints 
Major secondary analyses are presented in Table 2. Both treatment groups showed worsening 
in all major secondary endpoints with no significant difference between treatment with 
CNTO3157 or placebo. Except for the AUC over 10 days post-inoculation for Pre-BD FEV1, the 
changes were numerically higher in the CNTO3157 group but not to a clinically-meaningful 
degree.  The changes in CSAS and CCSS scores from pre-inoculation baseline are shown in 
Figure 5. Following HRV-16 inoculation, both treatment groups showed acute elevations in 
mean scores for both symptom scales, which peaked around Day 3 post-inoculation but 
resolved more quickly in the placebo group. The scores for the CSAS and CCSS were numerically 
greater for those subjects on CNTO3157 compared with placebo.  
There was a trend for improvement in TNOSS scores (p=0.07) for the CNTO3157 group 
compared to placebo at Week 4. The CCSS and CSAS scores were stable in both treatment 
groups during this phase.   
Figure 6 shows the percentage change from baseline for pre-BD FEV1 during the treatment 
phase before HRV-16 inoculation in Part 2 from the mITT analysis set, to evaluate the impact of 
CNTO3157 vs placebo on lung function after HRV-16 inoculation. There were no significant or 
clinically meaningful differences for pre-BD FEV1 between CNTO 3157 and placebo.   
The pharmacokinetic (PK) profiles of CNTO3157 in Part 1 and Part 2 were similar to the profiles 
seen in the first in human study (NCT01195207) for similar doses and dosing regimens (data not 
shown). Only 1 subjects in Part 2 had antidrug antibodies. See Section E4 of the online 
repository for further details.  
Safety 
There were no serious adverse events in Part 1 or Part 2. In Part 2, five CNTO3157 treated 
subjects (17%) had asthma exacerbations post-inoculation. Two of the 5 subjects had protocol-
defined severe exacerbations (use of systemic steroids). The 2 severe exacerbations occurred 
on Days 3, and 13 post-inoculation while the 3 moderate exacerbations occurred on Days 2, and 
at Weeks 7 and 11 post-inoculation. All of the post-inoculation asthma exacerbations occurred 
in subjects treated with CNTO3157. More detailed safety information is presented in Section E6 
and Table E1 in the online repository. 
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Viral load and infectivity 
Viral load was not significantly different between the treatment groups (data not shown).  
Biomarkers   
During the treatment phase, FENO was stable in both treatment groups with no significant 
difference after the treatment phase compared with the pre-treatment baseline (p=0.91). FENO 
showed slight increases in both treatment groups after inoculation compared with the pre-
HRB16 inoculation baseline but returned to pre-inoculation levels during follow-up evaluations 
with no significant difference between treatment groups (data not shown).   
Nasal lavage 
In Part 2 acute phase proteins were significantly up-regulated selectively in the CNTO3157 
group. C reactive protein (CRP) was significantly elevated on CNTO3157 compared to pre-
inoculation on Days 3 and 4 post-inoculation, and on Day 4 post-inoculation in the placebo 
group, with significantly higher elevations in the CNTO3157 group compared to the placebo 
group. IL-6 was significantly elevated in both treatment groups on Days 3 and 4 post inoculation 
(See online supplement Figure E1). 
IFN-induced chemokines CXCL10 and CXCL11 were up-regulated in both the placebo and 
CNTO3157 groups in Part 2. Figure E2 (online supplement) shows the AUC and maximal value 
for CXCL10 in Part 1 and Part 2 after inoculation with HRV-16. For Part 1, there was a non-
significant suppression of AUC CXCL10 (p=0.19) and maximal CXCL10 (p=0.58) in the CNTO3157 
group vs. the placebo group, whereas in Part 2, there was a trend for elevation of AUC CXCL10 
(p=0.08), and significant elevation of maximal CXCL10 (p=0.03) in the CNTO3157 group vs. the 
placebo group.  There was significant suppression of AUC and maximal CXCL10 levels (p=0.01; 
p=0.01, respectively) for the placebo group in Part 2 (asthma) compared to Part 1 (healthy 
subjects) suggesting an intrinsic suppression of CXCL10 responses to viral inoculation in asthma, 
not seen in the CNTO3157 group.    
Of note, several Type 2-associated analytes were modestly increased by HRV-16 in CNTO3157 
but not on placebo, including IgE, IL-5 and soluble IL-33 receptor (IL-1 R4) (See Figure E3, online 
supplement).   
From exploratory analyses of nasal lavage analytes measured using the SomaLogic SOMAscan 
v3 platform, all analytes significantly increased (FDR<0.05) at least 2-fold (day 4/baseline) in 
asthma patients after RV16 infection in CNTO 3157 treatment group and where such change 
was at least 2-fold (p<0.05) that in the placebo group are reported in Table E2 in the Online 
Repository. These results further support the observations that inflammation induced with 
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RV16 infection, including up-regulation of acute phase proteins, leukocyte chemoattractant 
chemokines, and neutrophil- and cytotoxic T cell- associated proteins, was further increased 
with CNTO 3157 treatment relative to placebo. 
No analytes were significantly modulated during the pre-inoculation treatment phase in either 
treatment group.  
Discussion 
This is the first study evaluating an inhibitory anti-TLR3 mAb in asthma, and to evaluate the 
effects of this mAB on experimental viral challenge. Despite preclinical support for the concept, 
antagonism of TLR3 signaling was ineffective in attenuating the effects of HRV-16 infection on 
lung function, or upper and lower airway symptoms in asthma.  
CNTO3157 demonstrated slightly worse outcomes compared with placebo for both the primary 
as well as the major secondary outcomes in asthmatics exposed to multiple weekly doses over 
3 weeks. CNTO3157 also failed to reduce nasal and serum CXCL10, a downstream marker for 
viral signaling. Finally, there were more moderate and severe asthma exacerbations reported in 
subjects receiving CNTO3157 compared to those receiving placebo after inoculation, which 
further suggests that CNTO3157 not only failed to attenuate the manifestations of HRV-16 
infection but may have made them slightly worse. In contrast, in healthy subjects there was 
some evidence to suggest that a single dose of CNTO3157 attenuated cold and chest 
symptoms, albeit in small numbers of subjects. 
Typically, viral challenge results in a clinical cold with upper airway symptoms that peak at 
around 3 days after inoculation. In healthy subjects, there are little to no chest symptoms, in 
contrast to asthma where chest symptoms (e.g. cough, wheeze, dyspnea, phlegm production) 
are more commonly seen.  Much more variable is the decline in lung function post-inoculation 
which can be absent or only minimal in mild and moderate asthma 
18-20
 in some reports, but has 
been reported to be greater in uncontrolled asthma with a lower FEV1 
21
. Our assumptions for 
this study were that HRV-16 challenge would result in a decline of 13% in pre-BD FEV1 and that 
CNTO3157 would attenuate this decline by 50% based on Message et al 
17
.  
To increase the probability of seeing a moderate FEV1 decline, we allowed not only mild but 
also moderate persistent asthmatics on ICS therapy, and allowed subjects with a pre-BD FEV1 as 
low as 65% of predicted. Despite these criteria, the enrolled population was well-controlled 
with preserved lung function, and this reduced the chance to demonstrate FEV1 decline (the 
maximal decline for pre-BD FEV1 on placebo was approximately 6%).  Considering all efficacy 
endpoints, and the excess of asthma exacerbations in the CNTO3157 group, these results 
provide compelling evidence that CNTO3157 compared with placebo was ineffective in 
attenuating and may have augmented the respiratory manifestations of HRV-16 in asthma.  
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Our primary hypothesis for the unsuccessful outcome of this study is that HRV-16 also 
interacted with other receptors, e.g. RIG-I, and MDA5, that were upregulated by the repeated 
dosing regimen in Part 2 and drove the increases in CXCL10 and other acute phase responses to 
HRV-16 
22, 23
.  Compatible with this notion is the significant elevation in Type 2 mediators (IgE, 
IL-5, sIL33R) seen in the CNTO3157 group but not in the placebo group in Part 2. Of note, recent 
evidence suggests that stimulation of RIG-I increases Type 2 inflammation through IL-33 
production 
24
.  Second, blockade of TLR3, by reducing interferon signaling, could conceivably 
have left viral replication unchecked resulting in worsening inflammation. This underpins a 
current theory attributing viral induced asthma exacerbations to an acquired deficiency in 
interferon responses 
25, 26
.  However, we found no evidence for an increased nasal viral load in 
those who received CNTO3157. Finally, the dose of CNTO3157 was more than adequate for 
blockade of TLR3 based on a prior study, where in an ex-vivo assay on whole blood stimulated 
with poly I:C, CNTO3157 administered with the same regimen suppressed cytokine release as 
described in the methods section.   
In keeping with our findings of increased Type-2 inflammation, recent observations from a 
human model of HRV infection in asthmatic subjects indicate a potential role of IL-33-
dependent Type 2 inflammation. Nasal lavage levels of IL-33, IL-4, IL-5 and IL-13 and bronchial 
lavage levels of IL-5 and IL-13 were significantly increased by HRV infection in subjects with 
asthma and nasal and bronchial IL-33 correlated with clinical outcomes and viral load 
16
. In 
another report, a subset of asthmatic subjects infected with HRV-16 (61%) had increased levels 
of secreted IL-25, a cytokine that can also augment Type-2 inflammation in the nasal mucosal 
fluid 
27
. We observed a similar Type-2-associated response to infection with HRV-16 in 
asthmatic subjects, with the additional novel finding that antagonism of TLR3 appears to 
enhance the Type-2 response, including levels of sIL-33R relative to the placebo group. Our 
findings are consistent with previous reports indicating higher levels of soluble IL-33R in 
response to respiratory syncytial virus infection in infants 
28
, and may represent a protective 
host response mechanism similar to that described in models of allergic asthma 
29
 and 
lipopolysaccharide-induced acute lung injury in mice 
30
.  
The HRV challenge model has been utilized for a number of years to study asthma 
pathogenesis, and has been helpful in elucidating the mechanisms underlying viral-induced 
asthma exacerbations as summarized in a recent review
31
. This challenge model has also been 
used extensively for common cold research. Based on our literature review, this study is one of 
the first to study an intervention with a mAb against TLR3in asthma.  Significant disadvantages 
of this model include the need for subjects to have low titers against HRV leading to a screen 
failure rate of ~50% for this reason alone, the need for parallel group designs, the meager FEV1 
response in well-controlled asthma, and the limited number of investigators available who are 
well-versed in the conduct of this approach. The additional requirement for this study for 
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subjects to be HSV-1 seropositive 
14
 contributed significantly to the screen failure rate which 
was in excess of 90%. Despite these challenges, this study, in a modest number of subjects, 
provided a clear no-go for efficacy of CNTO3157 as an intervention to reduce asthma 
exacerbations. 
Current approaches to reduction of asthma exacerbations include inhaled steroids, and 
emerging anti-inflammatories including anti-IgE, anti-IL-4R, anti-IL-13 and anti-IL-5 mAbs. 
Despite these interventions, there is still significant unmet need with regards to the prevention 
of exacerbations including particularly in those who do not meet the Type 2 inflammatory 
phenotype suitable for these mAb therapies e.g. anti-IL-13 or anti-IL-5 mAbs. A diametrically 
opposite approach to blockade of TLR3 which inhibits the interferon axis, is the administration 
of nebulized IFN which aims to boost antiviral host defense. This approach showed efficacy for 
ACQ, PEFR, and moderate asthma exacerbations in a post hoc analysis 
32
.  In this regard ACQ 
has been shown to be a strong predictor of future risk of exacerbations 
33
.  
Limitations of this study include the milder than expected severity and good asthma control of 
the asthmatic participants which may have reduced the chances of observing any benefit from 
TLR3 blockade. Enrollment of mild controlled asthmatic was intentional, as we were concerned 
about recruiting more severe asthmatic subjects and exposing them to a HRV-16 strain 
untested in asthmatics together with an anti-TLR3 antibody. The trends for worse outcomes in 
asthmatics on active drug compared to placebo and the imbalance in exacerbations supports 
our decision to focus on milder asthma for this study.  If this study had proven positive, we 
planned to study moderate-severe asthma in the next protocol. Secondly, while it is possible 
that the HRV-16 strain used was not as virulent as natural RV strains, in a prior study of this 
HRV-16 strain in healthy volunteers (NCT01466738), nasal symptom severity scores were 
comparable to those seen in natural colds (personal communication RBT), so we believe this 
strain was virulent. The 5 asthma exacerbations reported after inoculation in Part 2 support this 
contention. Finally, the impact of a single dose of CNTO3157 in the asthmatic cohort as utilized 
in Part 1, the healthy control group where symptoms were suppressed, might have led to a 
similar outcome in the asthmatic subjects by providing less time for induction of by-pass pro-
inflammatory pathways.  
In summary, CNTO3157, a TLR3 antagonist mAb, was ineffective in attenuating the impact of a 
HRV-16 challenge on asthma control, asthma symptoms and lung function. Other approaches, 
including blockade of multiple pathways, and antiviral agents, need to be sought for this high 
unmet medical need.  
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Figure legends 
Figure 1: Study design for Part 1 and Part 2. In Part 1, healthy volunteers received 10mg/kg of CNTO3157 
or placebo IV, and were then inoculated with HRV-16 within 72 hours and monitored closely for 10 days 
post inoculation with safety follow-up visits at weeks 4 and 8.  In Part 2, mild-moderate persistent 
asthmatics  received 10mg/kg, 3mg/kg, 3mg/kg and 3mg/kg of CNTO3157 or placebo IV at weekly 
intervals and were then inoculated with HRV-16 within 72 hours and monitored closely for 10 days post 
inoculation with safety follow-up visits at weeks 7 and 11.     
Figure 2: Disposition of participants for Part 1 (healthy subjects) and Part 2 (mild-to moderate persistent 
asthma). Where reasons for discontinuation are recorded as “other”, there is no documented reason in 
the database. AE= adverse events. 
Figure 3: Change over the 10-day post-inoculation from pre-inoculation baseline in mean (±SD) CSAS and 
CCSS (symptom scales) for Part 1 (healthy subjects), where there was a significant attenuation of both 
symptom scales on CNTO3157 (n=8) vs placebo (n=4).  
Figure 4: The primary endpoint, % change from pre-inoculation baseline in LS mean (SE) Pre-BD FEV1 
(mITT HRV-16 analysis set) for CNTO3157 and placebo in Part 2 (persistent asthmatic subjects). There 
was no significant difference for maximal fall or AUC day 1-Day 10 post-inoculation between CNTO3157 
and placebo.   
Figure 5:  Change in mean (SD) CSAS and CCSS post HRV inoculation from pre-inoculation baseline over 
the 10-day post-inoculation period for Part 2 (persistent asthmatic subjects) where both symptom scales 
were numerically higher on CNTO3157. 
Figure 6: For the mITT analysis set, percentage change from screening baseline in LS mean (SE) Pre-BD 
FEV1 for CNTO3157 and placebo in Part 2 during the treatment phase only (before HRV-16 inoculation). 
This demonstrates the effect of blockade of TLR3 compared to placebo on lung function. While there 
was a numerical difference between CNTO 3167 and placebo, this was not significant.  
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Table 1: Demographic and Disease characteristics for Part 2 
 Placebo  CNTO3157  
All Randomized Subjects (n) 31 32 
Age (years) Mean (SD) 38.1 (12.15) 39.6 (14.28) 
Female 10 (32.3%) 12 (37.5%) 
Male 21 (67.7%) 20 (62.5%) 
Race 
   Asian 1 (3.2%) 0 
   Black / African American 1 (3.2%) 0 
   Other 0 1 (3.1%) 
   White 29 (93.5%) 31 (96.9%) 
BMI (kg/m
2
) Mean (SD); range 26.1 (3.5); 20.3-38.6 25.7 (3.8); 19.4-34.3 
pre-BD FEV1 % predicted; mean (SD) 89.65 (12.44) 88.70 (10.83) 
Log FENO [ppb]–mean (SD) 3.73(0.63) 3.50 (0.80) 
Reported Allergies 51.6% 34.4% 
ACQ7 [0–6]; mean (SD) 0.65 (0.43) 0.78 (0.54) 
Blood Eosinophils (x 10
9
/L); mean (SD) 0.197 (0.1009) 0.178 (0.1650) 
ICS Use – Yes 22 (71.0%) 18 (56.3%) (p=0.23) 
BMI: body mass index; SD: standard deviation; pre-BD: pre-bronchodilator; FEV1: forced expired volume in 1 
second; FENO: fractional concentration of exhaled nitric oxide; ACQ: asthma control questionnaire; ICS: inhaled 
corticosteroids. There were no significant between-group differences for demographic and disease 
characteristics.    
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Table 2: Major secondary endpoints assessed as change in the 10 day post-inoculation period in Part 2  
Mean (SD) LS mean CNTO3157/placebo P value 
AUC of the % change from pre-inoculation in pre-BD FEV1 -4.26 (11.06)/-13.04 (12.11) 0.60 
AUC of the change from pre-inoculation in the CCSS 48.9 (9.87)/34.5 (10.63) 0.33 
AUC of the change from pre-inoculation in the CSAS 32.2 (6.09)/25.0 (6.56) 0.43 
AUC of the change from pre-inoculation in AM PEFR -183.2 (72.67)/-8.5 (79.64) 0.11 
Change from baseline in ACQ7 symptom scores 0.20 (0.68)/0.06 (0.62) 0.43 
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GEFCCSS01: Change from Baseline in CSAS and CCSS in Part 1 from Day of Inoculation Over 
Time 
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Online Supplement 
Background 
Extensive human in vitro and murine in vivo experiments supported the hypothesis that CNTO 3157 would be an effective 
agent to suppress the inflammatory effects induced by rhinovirus infection1-6. 
E1: Dosing rationale 
The PK profile (data not shown) from the Ph1 first in human multiple ascending dose study demonstrated increasing 
trough concentrations with each the second, third and fourth dose given at weekly intervals, presumed to be due to 
incomplete occupation of the receptor by CNTO3157.  In addition, there was complete inhibition of cytokine release in 
whole blood stimulated with poly I:C (IL1b, IL6, IL12p40 and IL12p70) at 7 days post dosing at 3mg/kg in healthy 
volunteers (data not shown).  In light of these data, a higher dose, 10mg/kg, was selected in Part 1, and a loading dose of 
10mg/kg, followed by 3 additional weekly doses of 3mg/kg, were selected for Part 2 to increase the certainty of TLR3 
blockade, and to inhibit cytokine release. 
E2: Biomarker analytical methods and analytes measured.  
Nasal lavage, serum, and sputum CXCL10 
Nasal wash, serum and sputum CXCL10. CXCL10 protein levels were assessed using the VeriPlex Human Interferon 9-Plex ELISA 
(PBL Assay Sciences, Piscataway, NJ). Additional protein markers were assessed using the aptamer-based SomaScan assay 
(Somalogic, Boulder, CO).  
HRV16 antibody titers.  
HRV16 neutralizing serum antibody titers were determined in a cell-based assay using MRC-5 cells. Briefly, MRC-5 cells were 
cultured under standard conditions in MRC-5 growth medium (EMEM with 10% heat inactivated FBS, 1M HEPES, L-Glutamine, 
NEAA and antibiotics).  Test sera were diluted in duplicate in a 96-well plate followed by addition of an equal volume of virus with an 
expected titer of 3.3 log10 TCID50/mL (2x103 TCID50/mL) and incubated for 30 minutes at 33°C. Dissocia ted MRC-5 cells were then 
added to the virus/sera and allowed to incubate for 5 days at 33°C when the plates were visually inspe cted by light microscopy to 
determine viral cytopathic effect (CPE). Cells within an individual well were considered to be HRV-16 antibody negative with CPE > 
50%. The neutralizing antibody titer was then calculated using the Reed Muench formula. In each assay a control consisting of a pool 
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of human sera of known neutralizing antibody titer and a commercially sourced anti-HRV-16 antiserum (ATCC) were used to confirm 
the assay was performing within specifications and to validate the results obtained with the test sera. Virology assays including the 
determination of HRV-16 and HSV1 neutralizing antibody titers, HRV-infectivity and RVP analysis were performed at hVIVO, London, 
UK(Formerly Retroscreen Virology). 
HRV-16 Infectivity Assay.  
Replication of HRV-16 in nasal wash samples was determined in a cell-based assay using MRC-5 cells. Briefly, MRC-5 cells were 
prepared for culture in a 96-well flat bottom plate and incubated for 1-2 days until 60-90% confluent. Nasal wash samples were 
added in quadruplicate to the 96-well plate containing MRC-5 cells, titrated using a 0.5 log10 dilution series and incubated at 33°C for 
5 days. Plates were then examined for viral CPE to determine the presence or absence of virus in each well. Virus titers were 
calculated using the Karber formula. A stock virus generated from the GMP challenge virus used in the study was used as a positive 
control. 
HSV screening. The HerpeSelect HSV-1 IgG ELISA (Focus Diagnostics) was used to determine the presence of HSV-1 antibodies 
in serum with interpretation of the test results in accordance with the manufacturer’s instructions.  
Respiratory Viral Panel (RVP). Throat swabs were used for a respiratory viral panel screen by multiplex qPCR. The viral panel 
screen tested for the presence of HRV-16 RNA, Influenza A RNA, Influenza B RNA, RSV RNA, Para Influenza 1, 2 and 3 RNA, 
Metapneumovirus RNA and adenovirus DNA. 
Section E3 
HRV challenge virus 
The strain of HRV16 used was isolated via nasal lavage from a subject in a clinical study at the University of Virginia. 
Good Manufacturing Practice guidelines were followed to manufacture the virus (Meridian Life Sciences, Memphis, TN, 
USA) and regulatory approval was obtained for its use in human subjects (investigational new drug number 014757).  The 
HRV16 strain was demonstrated to cause a classical upper respiratory infection without safety concerns at total doses of 
approximately 100 and 1000 TCID50/mL in 2 cohorts of healthy volunteer characterization study (data not shown).  
For the study reported here, HRV16 at a total dose of approximately 1000 TCID50/mL, in a volume of approximately 1.0 
mL, was administered by instillation with a pipette (divided into 2 instillations per naris). A confirmed infection with HRV16 
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was defined as a positive culture from nasal lavage at any time in the 5 days post-inoculation, and/or a 4-fold serological 
conversion to HRV16 assessed at the week 8 or 11 visits.   
Before inoculation, nasal lavage was cultured for the presence of viruses including HRV but also other viruses e.g. 
influenza.  
Section E4.  
Pharmacokinetics and Immunogenicity 
The pharmacokinetic (PK) profiles of CNTO3157 in Part 1 and Part 2 were similar to the profiles seen in the first in human 
study (NCT01195207) for similar doses and dosing regimens (data not shown). No apparent differences in serum 
CNTO3157 concentrations over 7 days following the first dose of 10 mg/kg administered by IV infusion were observed 
when comparing healthy subjects in Part 1 with asthmatic subjects in Part 2. Also, there were no apparent changes in 
serum CNTO3157 concentration-time profiles after the inoculation of HRV16. All subjects treated with CNTO3157 in Part 
1 were negative for antidrug antibodies (ADA) while only 1 subject in Part 2 (3.3% of all subjects) tested positive for ADA 
with no impact on this subject’s PK profile.  
Section E5. Viral load and biomarkers.  
Viral load 
HRV16 replication was determined in a cell-based assay and represented as log tissue culture infective dose (TCID)50 
post-inoculation. The replication profile was not significantly different between the treatment groups (data not shown).  
Of note, 1 subject in Part 1 (on CNTO3157) and 2 subjects in Part 2 (one on CNTO3157 and 1 on placebo) were positive 
for HRV16 at the pre-inoculation visit, and 1 subject in Part 1 on CNTO3157 was positive for influenza B at Day 10 post-
inoculation. These subjects were excluded from biomarker analyses but not excluded from the clinical analysis. 
Nasal lavage 
In Part 1, the cystatins, (CST)-1, -2, -4, and -5 were upregulated on CNTO3157 to a greater degree than placebo, while 
CD27, IL-37, cathepsin V, and carbonic anhydrase 6 were up-regulated on CNTO3157 alone. IFN-induced chemokines 
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CXCL10/IP-10 and CXCL11/ITAC were up-regulated in both placebo and CNTO3157 groups, demonstrating an 
attenuated rise but incomplete inhibition of IFN activity by CNTO3157 compared with placebo. 
Section E6 
Safety Part 2: The AEs are presented in 4 phases: 1) high dose (10mg/kg or placebo), 2) low dose (3mg/kg administered 
3 times at weekly intervals), 3) from virus inoculation to end of study, and 4) from randomization to end of study.   No 
deaths, serious AEs, or other significant AEs occurred in Part 2 of the study. The vast majority of AEs were mild in 
severity. If judged to be related, the majority of adverse events were reported as very likely related to HRV16. 
Table E1 (abbreviated) presents asthmatic subjects with 1 or more treatment-emergent adverse events (TEAEs) that 
occurred in at least 5% of subjects.  Of note, the highest number of subjects with at least 1 AE was in the virus-end (of 
study) phase as might be expected. For the treatment phase, more of the reported AEs occurred in the low-dose period 
(Weeks 2, 3 and 4 during which subjects received CNTO3157 3mg/kg) than in the high-dose period (following the 10 
mg/kg infusion). Slightly more subjects in the CNTO3157 group reported respiratory AEs than in the placebo group.  
There was no imbalance between the CNTO3157 and placebo groups for infections including oral herpes.  
Six subjects (5 in the CNTO3157 group and 1 in the placebo group) met the protocol-defined criteria of non-serious 
moderate or severe exacerbations during Part 2 of the study. The single subject in the placebo group had a protocol-
defined moderate asthma exacerbation during the treatment period consisting of multiple events characterized by 
decreases in peak expiratory flow rate (PEFR) and increased rescue medication use.  
Five CNTO3157 treated subjects (17%) had asthma exacerbations post-inoculation. Two of the 5 subjects had protocol-
defined severe exacerbations (use of systemic steroids). The 2 severe exacerbations occurred on Days 3, and 13 post-
inoculation while the 3 moderate exacerbations occurred on Days 2, and at Weeks 7 and 11 post-inoculation. All of the 
post-inoculation asthma exacerbations occurred in subjects treated with CNTO3157. 
Section E7: Biomarkers.  
Table E2 presents the nasal lavage analytes in Part 2 asthma that were significantly elevated post viral challenge.  
Figures E1, E2 and E3 present the biomarkers and are discussed in the results section of the main paper.  
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Figure E1. Changes in acute phase reactants in nasal lavage. For (A) study part 1 in healthy control subjects and (B) part 
2 in persistent asthma subjects, relative changes in nasal lavage levels of IL-6 (top panels) and CRP (bottom panels), 
expressed as log2-transform of within-subject ratios of post-inoculation (INOC) visit over pre-inoculation baseline levels (y-
axis), are displayed for each subject by time point post-inoculation (x-axis). * p<0.05 for change from baseline within-
treatment group; † p<0.05 CNTO 3157 vs. placebo, at indicated time point. 
Figure E2. Changes in CXCL10 levels in nasal lavage. (A) Area-under-curve (AUC) and (B) maximum value for relative 
changes in nasal lavage levels of CXCL10 (expressed as log2-transform of within-subject ratios of post-inoculation (INOC) 
visit over pre-inoculation baseline levels), from day of inoculation to day 10 post-inoculation with RV16, stratified by study 
part and treatment group. * p<0.05 CNTO 3157 vs. placebo for study part 2. 
Figure E3. Changes in Th2 cytokines in nasal lavage. For study Part 2, relative changes in nasal lavage levels of (A) IgE, 
(B) soluble IL-1R4 (IL-33R), and (C) IL-5, expressed as log2-transform of within-subject ratios of post-inoculation (INOC) 
visit over pre-inoculation baseline levels (y-axis), are displayed for each subject by time point post-inoculation (x-axis). * 
p<0.05 for change from baseline within-treatment group, at indicated time point. 
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Table E1: Number of Subjects With 1 or More Treatment-Emergent Adverse Events by in Part 2; Safety Analysis Set  
 
PBO CNTO3157  
 
High Dose 
Period  
Low Dose 
Period  Virus ➝ End  Treat ➝ End  
High Dose 
Period  
Low Dose 
Period  Virus ➝ End  Treat ➝ End  
n 30 25 25 30 31 30 30 31 
Subjects with 1 or more AEs 13 (43.3%) 10 (40.0%) 16 (64.0%) 25 (83.3%) 8 (25.8%) 13 (43.3%) 21 (70.0%) 25 (80.6%) 
System organ class/preferred term         
Respiratory, thoracic and mediastinal disorders 3 (10.0%) 2 (8.0%) 7 (28.0%) 11 (36.7%) 2 (6.5%) 1 (3.3%) 11 (36.7%) 12 (38.7%) 
Asthma 2 (6.7%) 0 1 (4.0%) 3 (10.0%) 0 0 5 (16.7%) 5 (16.1%) 
Cough 1 (3.3%) 0 1 (4.0%) 2 (6.7%) 2 (6.5%) 0 2 (6.7%) 3 (9.7%) 
Wheezing 0 0 0 0 1 (3.2%) 1 (3.3%) 2 (6.7%) 3 (9.7%) 
Dyspnea 0 0 1 (4.0%) 1 (3.3%) 0 0 2 (6.7%) 2 (6.5%) 
Oropharyngeal pain 0 1 (4.0%) 1 (4.0%) 2 (6.7%) 0 0 2 (6.7%) 2 (6.5%) 
Epistaxis 0 0 2 (8.0%) 2 (6.7%) 0 0 1 (3.3%) 1 (3.2%) 
Rhinitis allergic 0 0 0 0 0 0 1 (3.3%) 1 (3.2%) 
Rhinorrhoea 0 0 1 (4.0%) 1 (3.3%) 0 0 1 (3.3%) 1 (3.2%) 
Asthma exercise induced 0 1 (4.0%) 0 1 (3.3%) 0 0 0 0 
Dysphonia 0 0 1 (4.0%) 1 (3.3%) 0 0 0 0 
Nasal congestion 0 0 1 (4.0%) 1 (3.3%) 0 0 0 0 
Nervous system disorders 2 (6.7%) 6 (24.0%) 5 (20.0%) 11 (36.7%) 1 (3.2%) 4 (13.3%) 7 (23.3%) 10 (32.3%) 
Headache 2 (6.7%) 5 (20.0%) 5 (20.0%) 10 (33.3%) 0 3 (10.0%) 6 (20.0%) 8 (25.8%) 
Dizziness 0 0 0 0 0 1 (3.3%) 1 (3.3%) 2 (6.5%) 
Syncope 0 0 0 0 1 (3.2%) 0 0 1 (3.2%) 
Migraine 0 1 (4.0%) 0 1 (3.3%) 0 0 0 0 
General disorders and administration site 
conditions 0 2 (8.0%) 3 (12.0%) 4 (13.3%) 3 (9.7%) 2 (6.7%) 5 (16.7%) 9 (29.0%) 
Infections and infestations 1 (3.3%) 0 8 (32.0%) 9 (30.0%) 1 (3.2%) 0 7 (23.3%) 7 (22.6%) 
Nasopharyngitis 0 0 4 (16.0%) 4 (13.3%) 1 (3.2%) 0 3 (10.0%) 4 (12.9%) 
Oral herpes 1 (3.3%) 0 1 (4.0%) 2 (6.7%) 0 0 2 (6.7%) 2 (6.5%) 
Rhinitis 0 0 2 (8.0%) 2 (6.7%) 0 0 2 (6.7%) 2 (6.5%) 
Otitis media 0 0 0 0 0 0 1 (3.3%) 1 (3.2%) 
Upper respiratory tract infection 0 0 1 (4.0%) 1 (3.3%) 0 0 1 (3.3%) 1 (3.2%) 
Injury, poisoning and procedural complications 1 (3.3%) 2 (8.0%) 6 (24.0%) 8 (26.7%) 0 2 (6.7%) 6 (20.0%) 7 (22.6%) 
Musculoskeletal and connective tissue disorders 1 (3.3%) 0 2 (8.0%) 3 (10.0%) 0 2 (6.7%) 4 (13.3%) 6 (19.4%) 
Gastrointestinal disorders 2 (6.7%) 1 (4.0%) 4 (16.0%) 6 (20.0%) 0 1 (3.3%) 4 (13.3%) 5 (16.1%) 
Skin and subcutaneous tissue disorders 3 (10.0%) 1 (4.0%) 0 4 (13.3%) 0 3 (10.0%) 0 3 (9.7%) 
Eye disorders 1 (3.3%) 0 0 1 (3.3%) 0 0 2 (6.7%) 2 (6.5%) 
Ear and labyrinth disorders 0 0 0 0 1 (3.2%) 0 0 1 (3.2%) 
Psychiatric disorders 0 0 0 0 0 1 (3.3%) 0 1 (3.2%) 
Immune system disorders 2 (6.7%) 0 0 2 (6.7%) 0 0 0 0 
Investigations 1 (3.3%) 0 0 1 (3.3%) 0 0 0 0 
Note: Percentages calculated with the number of randomized, treated subjects in each study phase as the denominator. Incidence is based on the number of subjects experiencing 
at least one AE, not the number of events. Adverse events are coded using the MedDRA version 15.1. The table has been abbreviated to focus on system organ classes of greater 
relevance to CNTO3157 and HRV16 
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Table E2: Part 2 asthma, day 4 post-RV16 inoculation up-regulated nasal lavage analytes* 
6Ckine Coagulation Factor IXab IgG Proteinase-3 
a1-Antitrypsin Coagulation Factor XI ILT-2 PSME1 
a2-Antiplasmin Dkk-4 ILT-4 resistin 
a2-HS-Glycoprotein ECM1 LBP RTN4 
Afamin Elastase LYVE1 SAA 
Angiotensinogen EMR2 M-CSF R SAP 
Antithrombin III Factor B MDC sCD163 
Apo A-I Factor H MMP-1 SHBG 
Apo E Factor I MMP-9 SHP-2 
BGH3 FCG3B Notch 1 SIG14 
C3 FETUB 
Nucleoside diphosphate 
kinase A Siglec-7 
C4 Fibrinogen OLR1 sL-Selectin 
C5 Fibronectin OMD SREC-I 
C5a Gro-b/g PCI Tenascin 
C5b, 6 Complex hnRNP A/B PCSK9 Thyroxine-Binding Globulin 
Calpastatin HSP 70 PF-4 TNF sR-II 
CaMKK alpha IGFBP-3 Properdin TSG-6 
Cathepsin S IGFBP-5 Protein C TSP4 
CLM6    
* For CNTO 3157 treatment group, analytes passing significance filter of FDR<0.05 and fold(Day4/baseline)>2 listed; bolded 
analytes pass filter of nominal p-value<0.05 for day3 vs. baseline in CNTO 3157 treatment group 
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